These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7681940)

  • 21. New developments in the clinical use of didanosine.
    Kahn J
    J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S47-50. PubMed ID: 8426301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
    Kline MW; Calles NR; Simon C; Schwarzwald H
    Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatal pancreatitis as a complication of therapy for HIV infection.
    Pelucio MT; Rothenhaus T; Smith M; Ward DJ
    J Emerg Med; 1995; 13(5):633-7. PubMed ID: 8530781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
    Moore RD; Keruly JC; Chaisson RE
    AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
    Barrios A; Rendón A; Negredo E; Barreiro P; Garcia-Benayas T; Labarga P; Santos J; Domingo P; Sánchez-Conde M; Maida I; Martín-Carbonero L; Núñez M; Blanco F; Clotet B; Sambeat MA; Gil P; Gonzalez-Lahoz J; Cooper D; Soriano V
    AIDS; 2005 Mar; 19(6):569-75. PubMed ID: 15802975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
    Kelleher T; Cross A; Dunkle L
    Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
    García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
    Bruzzese VL; Gillum JG; Israel DS; Johnson GL; Kaplowitz LG; Polk RE
    Antimicrob Agents Chemother; 1995 May; 39(5):1050-3. PubMed ID: 7625787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus.
    Dutta SK; Ting CD; Lai LL
    Am J Gastroenterol; 1997 Nov; 92(11):2044-8. PubMed ID: 9362189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatitis in pediatric human immunodeficiency virus infection.
    Miller TL; Winter HS; Luginbuhl LM; Orav EJ; McIntosh K
    J Pediatr; 1992 Feb; 120(2 Pt 1):223-7. PubMed ID: 1370962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
    Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
    Ruxrungtham K; Kroon ED; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling GJ; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
    AIDS; 2000 Jul; 14(10):1375-82. PubMed ID: 10930152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pancreatic disease in patients with HIV treated with didanosine (DDI)].
    Ortega González E; Martín Herrera A; López de Medrano V; de Lelis FP; Ronda Gasulla FA; Gil Egea M; Ballester Belda E; Herrera Ballester A
    Rev Esp Enferm Dig; 1996 Feb; 88(2):114-7. PubMed ID: 8664067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.
    Grasela TH; Walawander CA; Beltangady M; Knupp CA; Martin RR; Dunkle LM; Barbhaiya RH; Pittman KA; Dolin R; Valentine FT
    J Infect Dis; 1994 Jun; 169(6):1250-5. PubMed ID: 8195601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.